^
    Back
    Association details:
    Biomarker:PD-L1 underexpression
    Cancer:Lung Adenocarcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    First line therapy...Adenocarcinoma, large cell, NSCLC NOS: Nivolumab + ipilimumab + pemetrexed + (carboplatin or cisplatin).
    Secondary therapy:
    pemetrexed; cisplatin; carboplatin
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression.